EFG International AG Makes New Investment in Biogen Inc. $BIIB

EFG International AG purchased a new position in shares of Biogen Inc. (NASDAQ:BIIB) in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 4,582 shares of the biotechnology company’s stock, valued at approximately $990,000.

Other hedge funds also recently modified their holdings of the company. Empowered Funds LLC grew its position in Biogen by 64.9% in the 1st quarter. Empowered Funds LLC now owns 7,054 shares of the biotechnology company’s stock worth $965,000 after purchasing an additional 2,777 shares during the last quarter. Focus Partners Wealth raised its position in shares of Biogen by 172.2% during the first quarter. Focus Partners Wealth now owns 10,173 shares of the biotechnology company’s stock valued at $1,392,000 after buying an additional 6,436 shares during the last quarter. Sivia Capital Partners LLC acquired a new position in shares of Biogen during the second quarter valued at about $216,000. Cerity Partners LLC lifted its stake in shares of Biogen by 15.3% in the second quarter. Cerity Partners LLC now owns 46,552 shares of the biotechnology company’s stock valued at $5,847,000 after buying an additional 6,184 shares during the period. Finally, NewEdge Advisors LLC lifted its stake in shares of Biogen by 13.4% in the second quarter. NewEdge Advisors LLC now owns 2,673 shares of the biotechnology company’s stock valued at $336,000 after buying an additional 316 shares during the period. 87.93% of the stock is owned by institutional investors.

Biogen Stock Up 0.1%

BIIB opened at $221.07 on Thursday. The firm has a market cap of $32.66 billion, a price-to-earnings ratio of 39.13, a PEG ratio of 6.88 and a beta of 0.17. The company has a debt-to-equity ratio of 0.39, a quick ratio of 1.26 and a current ratio of 1.87. The firm’s 50-day simple moving average is $206.87 and its 200-day simple moving average is $195.38. Biogen Inc. has a twelve month low of $131.52 and a twelve month high of $222.85.

Biogen (NASDAQ:BIIB) last announced its quarterly earnings results on Wednesday, July 29th. The biotechnology company reported $3.60 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.94 by $0.66. The firm had revenue of $2.74 billion during the quarter, compared to the consensus estimate of $2.46 billion. Biogen had a net margin of 8.32% and a return on equity of 11.18%. The firm’s quarterly revenue was up 3.4% on a year-over-year basis. During the same period last year, the firm posted $5.47 EPS. Biogen has set its FY 2026 guidance at 12.000-13.000 EPS. Equities research analysts anticipate that Biogen Inc. will post 12.39 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on the company. Needham & Company LLC boosted their price objective on Biogen from $255.00 to $256.00 and gave the company a “buy” rating in a research report on Monday, June 29th. Citigroup raised their target price on Biogen from $200.00 to $215.00 and gave the stock a “neutral” rating in a research report on Monday, August 3rd. Piper Sandler reiterated an “overweight” rating on shares of Biogen in a research note on Tuesday, July 14th. Mizuho boosted their price target on shares of Biogen from $221.00 to $241.00 and gave the company an “outperform” rating in a report on Tuesday, August 4th. Finally, Rothschild & Co Redburn increased their price objective on shares of Biogen from $180.00 to $190.00 in a research note on Thursday, April 30th. One equities research analyst has rated the stock with a Strong Buy rating, eighteen have given a Buy rating, thirteen have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $227.79.

Biogen Company Profile

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.